University-driven innovation is a cornerstone of societal progress, as academic institutions play a pivotal role in advancing research and technology that fuel economic growth, enhance quality of life, and address global challenges. With access to federal grants and a collaborative environment, universities are uniquely positioned to transform groundbreaking ideas into real-world solutions. Recognizing the importance of supporting these efforts, leaders in both Houses of Congress are aiming to make life a bit easier for universities that hope to innovate industry with federal grant dollars.  Senators Chris Coons (D-DE) and Thom Tillis (R-NC) have introduced the Improving Efficiency to Increase Competition Act (“the Act”) to amend the Bayh-Dole Act (“Bayh-Dole”).  Both Senators have expressed hope that this legislation will make it easier for institutions of higher learning to access federal funds and drive innovation into the future.

Passed in 1980, Bayh-Dole enables universities, small businesses, and non-profit research institutions to patent and monetize inventions developed with the aid of federally funded research programs.  Bayh-Dole has been credited with fostering competition, innovation, and economic growth through America’s institutions of higher learning.  While this is an undeniable boon to America’s academic and economic progress, the legislation also contains outdated reporting requirements that burden the very universities it intends to benefit.

Under Bayh-Dole, government grantees or contractors must report any and all intellectual property developed with federal funding.  While simple in theory, it is anything but in practice.  Each government agency offering intellectual property grants has its own methods for reporting developed projects, has various forms of communicating with grantees, and maintains its own standards for retention of a grantee’s intellectual property.  All of this leaves universities dealing with a dizzying array of bureaucratic red tape that obfuscates which agency needs what when for the institution to patent, license, and monetize its inventions.  Legislators on both sides of the aisle have come together to ease this burden. 

The Act is Congress’s attempt to rewrite the federal grant process for intellectual property.  It directs the Government Accountability Office’s (“GAO”) Comptroller General to conduct a study on these grant disclosure processes.  With a goal of reducing barriers to funding and increasing efficiency in grant delivery and product monetization, the Act will ask the GAO to determine how grantees of varying size, budgets, specialties, and locations are hampered by existing regulations and how to better enable them to access grant funding.  This means that universities with differing sizes and focuses across the country should expect to benefit.  If passed, the goal is for institutions of higher learning to have an easier time continuing to monetize their commercial innovations, driving the American economy forward for generations to come.

As the Act progresses through Congress, we will closely follow its developments and provide updates on how it may influence the landscape of academic innovation and intellectual property management. This legislation holds promise for reducing the bureaucratic hurdles that universities currently face and could significantly enhance their ability to bring groundbreaking ideas to market. Stay tuned for further insights as we track and provide commentary on the potential effects the Act may have on fostering research and driving future economic growth.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Michael Beckwith Michael Beckwith

Michael Beckwith is a law clerk in the Litigation Department.

Michael earned his J.D. from New York University School of Law and his B.A.., cum laude, from Binghamton University. While in law school, Michael was a Human Rights Scholar at the Center…

Michael Beckwith is a law clerk in the Litigation Department.

Michael earned his J.D. from New York University School of Law and his B.A.., cum laude, from Binghamton University. While in law school, Michael was a Human Rights Scholar at the Center for Human Rights and Global Justice, was an International Law and Human Rights Fellow, and served as Managing Editor of the Journal for Legislation and Public Policy.

Photo of Baldassare Vinti Baldassare Vinti

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies…

Baldassare (“Baldo”) Vinti is the head of Proskauer’s Intellectual Property Litigation Group.

Baldo is a first-chair trial lawyer known for navigating complex, bet-the-company intellectual property disputes across industry verticals and next-generation technologies. With over 25 years of experience, Baldo represents leading global companies and universities in patent, trade secret, false advertising, consumer class actions and technology-related breach of contract litigation in federal and state courts as well as before the International Trade Commission.

Baldo is particularly sought after for his courtroom skill and strategic depth, having led trials, arbitrations and appeals in high-stakes disputes involving technologies ranging from pharmaceuticals and medical devices to encryption, digital media, diagnostics, mobile platforms and software. Baldo has represented global corporations, including Arkema S.A., British Telecommunications PLC, Church & Dwight Co., Inc., Henry Schein, Inc., Maidenform Brands Inc., Mitsubishi Electric Corp., Ossur North America Inc., Panasonic Corp., Sony Corp., Welch Foods, Inc. and Zenith Electronics LLC.

With a background in pharmacy, Baldo brings deep domain expertise to pharmaceutical litigation. He has a proven record of driving successful outcomes in complex pharmaceutical milestone payment, royalty and licensing disputes—often stemming from collaboration agreements, co-development deals, and M&A transactions—where the financial and strategic stakes run high.

In addition to representing corporate clients, Baldo works closely with university innovation and technology transfer offices to maximize the financial return of research investments. He develops tailored IP asset optimization strategies and aggressively enforces intellectual property rights to protect and monetize core innovations—whether through high-value licensing agreements, shaping and advancing spin-out company development, or successful litigation.

Baldo also provides strategic counsel on IP due diligence, complex licensing, IP structuring, patentability and freedom-to-operate analyses, and infringement and validity opinions. He advises boards and executive teams on aligning IP strategy with business objectives, mitigating risk and maximizing the value of innovation assets.

A frequent author and commentator on intellectual property topics, Baldo has been quoted in the National Law Journal, Bloomberg BNA, Law360, Westlaw Journal and Inside Counsel magazine. He is also a regular contributor to articles published in Medical Product Outsourcing magazine that deal with the medical device industry.

Baldo served as a judicial intern for Hon. John E. Sprizzo of the United States District Court for the Southern District of New York and for Hon. Charles A. LaTorella of the New York Supreme Court.